Cartesian Therapeutics In... (RNAC)
17.58
-1.26 (-6.69%)
At close: Mar 03, 2025, 3:59 PM
17.50
-0.46%
After-hours: Mar 03, 2025, 04:00 PM EST
No 1D chart data available
| Bid | 17 |
| Market Cap | 452.25M |
| Revenue (ttm) | 172.31M |
| Net Income (ttm) | -880M |
| EPS (ttm) | -55.05 |
| PE Ratio (ttm) | -0.32 |
| Forward PE | -8.68 |
| Analyst | Buy |
| Ask | 22 |
| Volume | 165,026 |
| Avg. Volume (20D) | 101,058 |
| Open | 18.45 |
| Previous Close | 18.84 |
| Day's Range | 17.47 - 18.60 |
| 52-Week Range | 11.66 - 41.87 |
| Beta | 0.71 |
About RNAC
Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's lead therapeutic gene therapy program is SEL-302 that is in Phase I clinical trial to enhance the treatment of methylmalonic acidemia. It is also developing biologic therapies, such as SEL-212 that is in Phase III clinical trials for ...
Industry Biotechnology
Sector Healthcare
IPO Date Jun 22, 2016
Employees 37
Stock Exchange NASDAQ
Ticker Symbol RNAC
Website https://selectabio.com
Analyst Forecast
According to 8 analyst ratings, the average rating for RNAC stock is "Buy." The 12-month stock price forecast is $41.5, which is an increase of 136.06% from the latest price.
Buy 87.50%
Hold 12.50%
Sell 0.00%
Next Earnings Release
Cartesian Therapeutics Inc. is scheduled to release its earnings on Mar 18, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
8 months ago
-35.02%
Cartesian Therapeutics shares are trading lower. T...
Unlock content with
Pro Subscription
10 months ago
+12.76%
Cartesian Therapeutics shares are trading higher after Leerink Partners initiated coverage on the stock with an Outperform rating and announced a $39 price target.
